

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. -61. (Cancelled)
62. (Cancelled)
63. – 67. (Cancelled)
68. (Previously Presented) A method for treating a patient, comprising:  
delivering an angioplasty balloon to a site along a lumen in the patient;  
inflating the balloon to contact a wall of the lumen at the site;  
locally delivering to the lumen wall at the site a volume of at least one  
bioactive agent selected from the group consisting of a des-methyl tocopherol, a phytyl  
substituted chromanol, and a palm oil agent, or a precursor, analog, or derivative  
thereof.
69. (Previously Presented) The method of claim 68, wherein said first  
bioactive agent is selected from the group consisting of a des-methyl tocopherol agent,  
a phytyl substituted chromanol agent, a gamma-tocopherol agent, a delta-tocopherol  
agent, a gamma-tocotrienol agent, a delta-tocotrienol agent, a palm oil agent, or a  
precursor, analog, or derivative thereof.
70. (Previously Presented) The method of claim 68, wherein the first bioactive  
agent comprises a gamma-tocopherol agent.
71. (Previously Presented) The method of claim 68, wherein said volume  
comprises a precursor of the first bioactive agent that comprises a DNA plasmid  
encoding the production of said first bioactive agent.
72. (Previously Presented) The method of claim 68, wherein said volume  
comprises a precursor of the first bioactive agent that comprises a viral or non-viral  
gene vector encoding the production of said first bioactive agent.

73. (Previously Presented) The method of claim 68, further comprising:  
delivering an endolumenal stent to the site;  
deploying the stent to contact the wall at the site; and  
delivering the volume into the wall at the site from the deployed stent.
74. (Previously Presented) The method of claim 73, further comprising:  
coating or adsorbing the stent with a delivery carrier containing the  
volume; and  
delivering the volume to the wall at the site via release from the delivery  
carrier.
75. (Previously Presented) The method of claim 68, further comprising:  
coupling said volume to the angioplasty balloon; and  
delivering said volume to the wall at the site by releasing the volume from  
the angioplasty balloon.
76. (Previously Presented) The method of claim 68, further comprising  
administering a therapeutic dose of said first bioactive agent in said volume in a manner  
providing a higher bioactivity of the first bioactive agent at said site than elsewhere in  
the body.
77. (Previously Presented) The method of claim 68, further comprising:  
in combination with said volume of first bioactive agent, delivering into the  
wall at the site a therapeutic dose of a second bioactive agent that is different from said  
first bioactive agent.
78. (Previously Presented) The method of claim 77, wherein said second  
bioactive agent comprises an anti-restenosis agent delivered in a manner that provides  
a higher bioactivity at said site than elsewhere in the body.
79. (Previously Presented) The method of claim 78, wherein said dose of anti-  
restenosis agent is delivered in a manner sufficient to inhibit restenosis at said site  
following balloon angioplasty or stent implantation.

80. (Previously Presented) The method of claim 78, wherein said anti-restenosis agent comprises at least one agent selected from the group consisting of sirolimus, tacrolimus, everolimus, ABT-578, paclitaxel, dexamethasone, 17-beta-estradiol, steroid, des-aspartate angiotensin I (DAA-1), angiotensin converting enzyme inhibitor (ACE inhibitor), angiotensin II receptor blocker, tachykinin, sialokinin, apocynin, pleiotrophin, exochelin, an iron chelator, VEGF, heparin, coumadin, clopidogrel, IIb/IIIa inhibitor, nitric oxide, a nitric oxide donor, an eNOS antagonist, a nitric oxide synthesis promoter, and a statin, or a precursor, analog, or derivative thereof, or a combination or blend thereof.

81. (Previously Presented) The method of claim 77, further comprising:  
locally delivering the first bioactive agent and second bioactive agent into the wall at the site.

82. (Previously Presented) The method of claim 80, further comprising:  
eluting at least one of said first bioactive agent and said second bioactive agent from the angioplasty balloon or an implanted stent into the wall at the site.

83. (Previously Presented) The method of claim 80, further comprising:  
systemically delivering the other of said first and second bioactive agents.

84. (Previously Presented) The method of claim 77, further comprising:  
eluting both the first and second bioactive agents from the angioplasty balloon or an implanted stent.

85. (Previously Presented) The method of claim 77, further comprising:  
coating an implantable endolumenal stent with a porous non-polymeric carrier matrix;  
holding the volume of first bioactive agent principally within the porous metal carrier matrix;  
delivering and deploying the stent to contact the wall at the site; and  
eluting the volume from the matrix into the wall at the site from the deployed stent.

86. (Previously Presented) A system for treating a patient, comprising:  
an angioplasty balloon that is deliverable to a site along a lumen in a patient and is inflatable to contact a wall of the lumen at the site;  
a volume of a pharmaceutically acceptable preparation of a first bioactive agent selected from the group consisting of des-methyl tocopherol, a phytol substituted chromanol, and a palm oil agent, or a precursor, analog, or derivative thereof; and  
a local drug delivery system coupled to the volume and configured to deliver the volume to the lumen wall at the site.

87. (Previously Presented) The system of claim 86, wherein said first bioactive agent is selected from the group consisting of a des-methyl tocopherol agent, a phytol substituted chromanol agent, a gamma-tocopherol agent, a delta-tocopherol agent, a gamma-tocotrienol agent, a delta-tocotrienol agent, a palm oil agent, or a precursor, analog, or derivative thereof.

88. (Previously Presented) The system of claim 86, wherein:  
said local drug delivery system comprises a carrier coupling the volume to at least one of the angioplasty balloon and an implantable endolumenal stent;  
said volume is held and deliverable to the wall at the site via release from the carrier.